EA035130B1 - Цистеиновая протеаза - Google Patents

Info

Publication number

EA035130B1

EA035130B1 EA201791773A EA201791773A EA035130B1 EA 035130 B1 EA035130 B1 EA 035130B1 EA 201791773 A EA201791773 A EA 201791773A EA 201791773 A EA201791773 A EA 201791773A EA 035130 B1 EA035130 B1 EA 035130B1

Authority

EA

Eurasian Patent Office

Prior art keywords

igg

ides

seq

polypeptide

sequence

Prior art date

2015-02-12

Links

• Espacenet
• Global Dossier
• Discuss

• 102000005927 Cysteine Proteases Human genes 0.000 title claims abstract description 43
• 108010005843 Cysteine Proteases Proteins 0.000 title claims abstract description 43
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 321
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 319
• 229920001184 polypeptide Polymers 0.000 claims abstract description 318
• 230000000694 effects Effects 0.000 claims abstract description 86
• 238000000034 method Methods 0.000 claims abstract description 70
• 238000004458 analytical method Methods 0.000 claims abstract description 29
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
• 201000010099 disease Diseases 0.000 claims abstract description 27
• 230000001404 mediated effect Effects 0.000 claims abstract description 17
• 238000011282 treatment Methods 0.000 claims abstract description 15
• 238000003776 cleavage reaction Methods 0.000 claims description 116
• 230000007017 scission Effects 0.000 claims description 114
• 235000001014 amino acid Nutrition 0.000 claims description 73
• 150000001413 amino acids Chemical class 0.000 claims description 66
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 59
• 230000005847 immunogenicity Effects 0.000 claims description 33
• 239000000203 mixture Substances 0.000 claims description 33
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 23
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 17
• 229930182817 methionine Natural products 0.000 claims description 16
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 15
• 108091033319 polynucleotide Proteins 0.000 claims description 15
• 102000040430 polynucleotide Human genes 0.000 claims description 15
• 239000002157 polynucleotide Substances 0.000 claims description 15
• 239000004472 Lysine Substances 0.000 claims description 14
• 235000003704 aspartic acid Nutrition 0.000 claims description 10
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 10
• 150000007523 nucleic acids Chemical group 0.000 claims description 10
• 239000004475 Arginine Substances 0.000 claims description 8
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
• 230000001580 bacterial effect Effects 0.000 claims description 8
• 230000001717 pathogenic effect Effects 0.000 claims description 8
• 235000018417 cysteine Nutrition 0.000 claims description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
• 239000013604 expression vector Substances 0.000 claims description 7
• 108091005804 Peptidases Proteins 0.000 claims description 6
• 210000004369 blood Anatomy 0.000 claims description 6
• 239000008280 blood Substances 0.000 claims description 6
• 239000003085 diluting agent Substances 0.000 claims description 6
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 5
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
• 239000004365 Protease Substances 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
• 241001465754 Metazoa Species 0.000 claims description 3
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
• 238000001727 in vivo Methods 0.000 abstract description 13
• 230000002265 prevention Effects 0.000 abstract description 2
• 229940024606 amino acid Drugs 0.000 description 65
• 238000012360 testing method Methods 0.000 description 60
• 238000003556 assay Methods 0.000 description 56
• 230000027455 binding Effects 0.000 description 41
• 238000004448 titration Methods 0.000 description 35
• 102000004190 Enzymes Human genes 0.000 description 31
• 108090000790 Enzymes Proteins 0.000 description 31
• 125000003275 alpha amino acid group Chemical group 0.000 description 28
• 239000000427 antigen Substances 0.000 description 25
• 108091007433 antigens Proteins 0.000 description 25
• 102000036639 antigens Human genes 0.000 description 25
• 210000002966 serum Anatomy 0.000 description 24
• 206010028980 Neoplasm Diseases 0.000 description 23
• 239000012634 fragment Substances 0.000 description 23
• 239000000499 gel Substances 0.000 description 23
• 239000003814 drug Substances 0.000 description 22
• 239000000126 substance Substances 0.000 description 21
• 239000003826 tablet Substances 0.000 description 21
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 20
• 238000012986 modification Methods 0.000 description 20
• 230000004048 modification Effects 0.000 description 20
• 238000002965 ELISA Methods 0.000 description 18
• 230000009471 action Effects 0.000 description 18
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 18
• 229940048921 humira Drugs 0.000 description 17
• 108090000623 proteins and genes Proteins 0.000 description 17
• 238000006467 substitution reaction Methods 0.000 description 17
• 238000002054 transplantation Methods 0.000 description 16
• 229940014556 xgeva Drugs 0.000 description 16
• 235000018102 proteins Nutrition 0.000 description 15
• 102000004169 proteins and genes Human genes 0.000 description 15
• -1 aliphatic amino acid Chemical class 0.000 description 14
• 239000000872 buffer Substances 0.000 description 14
• 238000010790 dilution Methods 0.000 description 14
• 239000012895 dilution Substances 0.000 description 14
• 238000002474 experimental method Methods 0.000 description 14
• 230000001965 increasing effect Effects 0.000 description 14
• 230000007935 neutral effect Effects 0.000 description 14
• 201000011510 cancer Diseases 0.000 description 13
• 210000004027 cell Anatomy 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 239000000523 sample Substances 0.000 description 13
• 238000002560 therapeutic procedure Methods 0.000 description 13
• 238000002360 preparation method Methods 0.000 description 12
• 229940124597 therapeutic agent Drugs 0.000 description 12
• 230000002209 hydrophobic effect Effects 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 10
• 230000029087 digestion Effects 0.000 description 10
• 210000002381 plasma Anatomy 0.000 description 10
• 239000000758 substrate Substances 0.000 description 10
• 239000013598 vector Substances 0.000 description 10
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• 241000699670 Mus sp. Species 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
• 239000002953 phosphate buffered saline Substances 0.000 description 9
• 230000001154 acute effect Effects 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 108020004705 Codon Proteins 0.000 description 7
• CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 7
• 206010025323 Lymphomas Diseases 0.000 description 7
• 230000000903 blocking effect Effects 0.000 description 7
• 230000003472 neutralizing effect Effects 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• 206010003571 Astrocytoma Diseases 0.000 description 6
• 208000003174 Brain Neoplasms Diseases 0.000 description 6
• 241000283707 Capra Species 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 6
• 206010018338 Glioma Diseases 0.000 description 6
• 239000004471 Glycine Substances 0.000 description 6
• 108060003951 Immunoglobulin Proteins 0.000 description 6
• 206010052779 Transplant rejections Diseases 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 125000003118 aryl group Chemical group 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 238000004422 calculation algorithm Methods 0.000 description 6
• 239000002299 complementary DNA Substances 0.000 description 6
• 230000000875 corresponding effect Effects 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 239000008273 gelatin Substances 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 235000019322 gelatine Nutrition 0.000 description 6
• 235000011852 gelatine desserts Nutrition 0.000 description 6
• 102000018358 immunoglobulin Human genes 0.000 description 6
• 238000001990 intravenous administration Methods 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 229940013982 octagam Drugs 0.000 description 6
• 150000003839 salts Chemical class 0.000 description 6
• 102000008186 Collagen Human genes 0.000 description 5
• 108010035532 Collagen Proteins 0.000 description 5
• 108091022930 Glutamate decarboxylase Proteins 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
• 208000034578 Multiple myelomas Diseases 0.000 description 5
• 102000035195 Peptidases Human genes 0.000 description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 description 5
• 108010076504 Protein Sorting Signals Proteins 0.000 description 5
• 208000021386 Sjogren Syndrome Diseases 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 241000193996 Streptococcus pyogenes Species 0.000 description 5
• 229960002964 adalimumab Drugs 0.000 description 5
• 210000004899 c-terminal region Anatomy 0.000 description 5
• 238000011088 calibration curve Methods 0.000 description 5
• 208000030239 cerebral astrocytoma Diseases 0.000 description 5
• 229920001436 collagen Polymers 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 208000030883 malignant astrocytoma Diseases 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 230000003287 optical effect Effects 0.000 description 5
• 210000003491 skin Anatomy 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 241000251468 Actinopterygii Species 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 238000012286 ELISA Assay Methods 0.000 description 4
• 208000032612 Glial tumor Diseases 0.000 description 4
• 208000017604 Hodgkin disease Diseases 0.000 description 4
• 208000008839 Kidney Neoplasms Diseases 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 206010038389 Renal cancer Diseases 0.000 description 4
• 208000000453 Skin Neoplasms Diseases 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 230000003460 anti-nuclear Effects 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 210000002308 embryonic cell Anatomy 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
• 230000002267 hypothalamic effect Effects 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 4
• 210000004153 islets of langerhan Anatomy 0.000 description 4
• 201000010982 kidney cancer Diseases 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 238000011321 prophylaxis Methods 0.000 description 4
• 235000019419 proteases Nutrition 0.000 description 4
• 229960004641 rituximab Drugs 0.000 description 4
• 201000000849 skin cancer Diseases 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 238000000954 titration curve Methods 0.000 description 4
• 229960003989 tocilizumab Drugs 0.000 description 4
• 230000000007 visual effect Effects 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• 208000030507 AIDS Diseases 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 102000007469 Actins Human genes 0.000 description 3
• 108010085238 Actins Proteins 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 102100029968 Calreticulin Human genes 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
• 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 102000008214 Glutamate decarboxylase Human genes 0.000 description 3
• 208000024869 Goodpasture syndrome Diseases 0.000 description 3
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 3
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
• 206010061252 Intraocular melanoma Diseases 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• 208000003445 Mouth Neoplasms Diseases 0.000 description 3
• 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
• 206010053159 Organ failure Diseases 0.000 description 3
• 206010033128 Ovarian cancer Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 201000011152 Pemphigus Diseases 0.000 description 3
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• 206010070834 Sensitisation Diseases 0.000 description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 description 3
• 201000005969 Uveal melanoma Diseases 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 230000002529 anti-mitochondrial effect Effects 0.000 description 3
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 238000012875 competitive assay Methods 0.000 description 3
• 230000002860 competitive effect Effects 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 229960001251 denosumab Drugs 0.000 description 3
• 150000002270 gangliosides Chemical class 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 238000011194 good manufacturing practice Methods 0.000 description 3
• 102000053391 human F Human genes 0.000 description 3
• 108700031895 human F Proteins 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 210000000244 kidney pelvis Anatomy 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 201000002575 ocular melanoma Diseases 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 238000011533 pre-incubation Methods 0.000 description 3
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 208000004124 rheumatic heart disease Diseases 0.000 description 3
• 230000008313 sensitization Effects 0.000 description 3
• 238000013207 serial dilution Methods 0.000 description 3
• 210000002460 smooth muscle Anatomy 0.000 description 3
• 201000011549 stomach cancer Diseases 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 201000002510 thyroid cancer Diseases 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• 238000012800 visualization Methods 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• 102000012002 Aquaporin 4 Human genes 0.000 description 2
• 108010036280 Aquaporin 4 Proteins 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 206010055128 Autoimmune neutropenia Diseases 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
• 206010004593 Bile duct cancer Diseases 0.000 description 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 206010006143 Brain stem glioma Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• 108090000549 Calreticulin Proteins 0.000 description 2
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 2
• 102000013602 Cardiac Myosins Human genes 0.000 description 2
• 108010051609 Cardiac Myosins Proteins 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 2
• 108010009685 Cholinergic Receptors Proteins 0.000 description 2
• 102000000503 Collagen Type II Human genes 0.000 description 2
• 108010041390 Collagen Type II Proteins 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 101710088194 Dehydrogenase Proteins 0.000 description 2
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 206010014967 Ependymoma Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
• 208000006168 Ewing Sarcoma Diseases 0.000 description 2
• 241001203952 Feia Species 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• 108010052778 Golgi Matrix Proteins Proteins 0.000 description 2
• 102000018884 Golgi Matrix Proteins Human genes 0.000 description 2
• 206010019263 Heart block congenital Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
• 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 108010036012 Iodide peroxidase Proteins 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
• 206010028424 Myasthenic syndrome Diseases 0.000 description 2
• 102000055324 Myelin Proteolipid Human genes 0.000 description 2
• 101710094913 Myelin proteolipid protein Proteins 0.000 description 2
• 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 2
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 102100038485 Nucleolar transcription factor 1 Human genes 0.000 description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
• 206010073338 Optic glioma Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• 241000721454 Pemphigus Species 0.000 description 2
• 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 2
• 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 2
• 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 241000194017 Streptococcus Species 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 101000588258 Taenia solium Paramyosin Proteins 0.000 description 2
• 108020005038 Terminator Codon Proteins 0.000 description 2
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
• 102000014267 Thyroid peroxidases Human genes 0.000 description 2
• 102100029337 Thyrotropin receptor Human genes 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 102000014701 Transketolase Human genes 0.000 description 2
• 108010043652 Transketolase Proteins 0.000 description 2
• 102100036790 Tubulin beta-3 chain Human genes 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 102000013127 Vimentin Human genes 0.000 description 2
• 108010065472 Vimentin Proteins 0.000 description 2
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 102000034337 acetylcholine receptors Human genes 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 208000027137 acute motor axonal neuropathy Diseases 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 229960000548 alemtuzumab Drugs 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• 102000004111 amphiphysin Human genes 0.000 description 2
• 108090000686 amphiphysin Proteins 0.000 description 2
• 230000001494 anti-thymocyte effect Effects 0.000 description 2
• 229960004669 basiliximab Drugs 0.000 description 2
• 229960003270 belimumab Drugs 0.000 description 2
• 229960002874 briakinumab Drugs 0.000 description 2
• 208000000594 bullous pemphigoid Diseases 0.000 description 2
• 208000002458 carcinoid tumor Diseases 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 230000009137 competitive binding Effects 0.000 description 2
• 201000004395 congenital heart block Diseases 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
• 206010061811 demyelinating polyneuropathy Diseases 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 229950009760 epratuzumab Drugs 0.000 description 2
• 201000004101 esophageal cancer Diseases 0.000 description 2
• 208000024386 fungal infectious disease Diseases 0.000 description 2
• 229940084434 fungoid Drugs 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 229960001743 golimumab Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 208000029824 high grade glioma Diseases 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000000899 immune system response Effects 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 230000001861 immunosuppressant effect Effects 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229930027917 kanamycin Natural products 0.000 description 2
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
• 229960000318 kanamycin Drugs 0.000 description 2
• 229930182823 kanamycin A Natural products 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 239000012160 loading buffer Substances 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 201000011614 malignant glioma Diseases 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 244000000010 microbial pathogen Species 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
• 210000004897 n-terminal region Anatomy 0.000 description 2
• 229960005027 natalizumab Drugs 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 229960003347 obinutuzumab Drugs 0.000 description 2
• 229950005751 ocrelizumab Drugs 0.000 description 2
• 229960002450 ofatumumab Drugs 0.000 description 2
• 229960000470 omalizumab Drugs 0.000 description 2
• 208000008511 optic nerve glioma Diseases 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 2
• 229960001972 panitumumab Drugs 0.000 description 2
• 210000003695 paranasal sinus Anatomy 0.000 description 2
• 201000001976 pemphigus vulgaris Diseases 0.000 description 2
• 239000000816 peptidomimetic Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 238000010532 solid phase synthesis reaction Methods 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229940035024 thioglycerol Drugs 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 108010040073 transcription factor UBF Proteins 0.000 description 2
• 206010044412 transitional cell carcinoma Diseases 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 210000003708 urethra Anatomy 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 229960003824 ustekinumab Drugs 0.000 description 2
• 208000037965 uterine sarcoma Diseases 0.000 description 2
• 229960004914 vedolizumab Drugs 0.000 description 2
• 210000005048 vimentin Anatomy 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• 108010022794 2',3'-Cyclic-Nucleotide Phosphodiesterases Proteins 0.000 description 1
• 102100040458 2',3'-cyclic-nucleotide 3'-phosphodiesterase Human genes 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• 102100032290 A disintegrin and metalloproteinase with thrombospondin motifs 13 Human genes 0.000 description 1
• 108091005670 ADAMTS13 Proteins 0.000 description 1
• 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
• 241001316595 Acris Species 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 102100036664 Adenosine deaminase Human genes 0.000 description 1
• 208000008958 Anti-N-Methyl-D-Aspartate Receptor Encephalitis Diseases 0.000 description 1
• 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 108010065524 CD52 Antigen Proteins 0.000 description 1
• 102100025221 CD70 antigen Human genes 0.000 description 1
• 229940126609 CR6261 Drugs 0.000 description 1
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 206010007281 Carcinoid tumour of the stomach Diseases 0.000 description 1
• 208000029713 Catastrophic antiphospholipid syndrome Diseases 0.000 description 1
• 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 description 1
• 102100027516 Cholesterol side-chain cleavage enzyme, mitochondrial Human genes 0.000 description 1
• 102000006449 Class 8 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 description 1
• 108010044226 Class 8 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 1
• 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 1
• 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 1
• 102100026735 Coagulation factor VIII Human genes 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 102100031144 Coilin Human genes 0.000 description 1
• 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 description 1
• 108010091326 Cryoglobulins Proteins 0.000 description 1
• 229940094664 Cysteine protease inhibitor Drugs 0.000 description 1
• 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
• 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• 102000003915 DNA Topoisomerases Human genes 0.000 description 1
• 108090000323 DNA Topoisomerases Proteins 0.000 description 1
• 102100036912 Desmin Human genes 0.000 description 1
• 108010044052 Desmin Proteins 0.000 description 1
• 102000011799 Desmoglein Human genes 0.000 description 1
• 108050002238 Desmoglein Proteins 0.000 description 1
• 241000447394 Desmos Species 0.000 description 1
• 102000011800 Desmosomal cadherin Human genes 0.000 description 1
• 108050002237 Desmosomal cadherin Proteins 0.000 description 1
• 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 229940126626 Ektomab Drugs 0.000 description 1
• 108010055196 EphA2 Receptor Proteins 0.000 description 1
• 108010055334 EphB2 Receptor Proteins 0.000 description 1
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
• 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
• 206010053177 Epidermolysis Diseases 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
• 101710097670 Extracellular cysteine protease Proteins 0.000 description 1
• 229940126611 FBTA05 Drugs 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 101710088083 Glomulin Proteins 0.000 description 1
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 206010018498 Goitre Diseases 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 108010078321 Guanylate Cyclase Proteins 0.000 description 1
• 102000014469 Guanylate cyclase Human genes 0.000 description 1
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
• 102100025255 Haptoglobin Human genes 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
• 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 1
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
• 101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
• 101000992283 Homo sapiens Optineurin Proteins 0.000 description 1
• 101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 description 1
• 101000861263 Homo sapiens Steroid 21-hydroxylase Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
• 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 1
• 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 101000841498 Homo sapiens UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 102000009438 IgE Receptors Human genes 0.000 description 1
• 108010073816 IgE Receptors Proteins 0.000 description 1
• 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 1
• 108010041100 Integrin alpha6 Proteins 0.000 description 1
• 102000000426 Integrin alpha6 Human genes 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
• 208000029523 Interstitial Lung disease Diseases 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 206010062038 Lip neoplasm Diseases 0.000 description 1
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 102100022742 Lupus La protein Human genes 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
• 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 102000003735 Mesothelin Human genes 0.000 description 1
• 108090000015 Mesothelin Proteins 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
• 102100023123 Mucin-16 Human genes 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
• 108090000235 Myeloperoxidases Proteins 0.000 description 1
• 102000003896 Myeloperoxidases Human genes 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
• 206010028767 Nasal sinus cancer Diseases 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• 102100035414 Neurofascin Human genes 0.000 description 1
• 101710189786 Neurofascin Proteins 0.000 description 1
• 208000010505 Nose Neoplasms Diseases 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 108010047956 Nucleosomes Proteins 0.000 description 1
• 102100031822 Optineurin Human genes 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• 102100034574 P protein Human genes 0.000 description 1
• 101710181008 P protein Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 206010034811 Pharyngeal cancer Diseases 0.000 description 1
• 206010034839 Pharyngitis streptococcal Diseases 0.000 description 1
• 101710177166 Phosphoprotein Proteins 0.000 description 1
• 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000033014 Plasma cell tumor Diseases 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• 102100038094 Protein-glutamine gamma-glutamyltransferase E Human genes 0.000 description 1
• 101710182788 Protein-glutamine gamma-glutamyltransferase E Proteins 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 102000013008 Semaphorin-3A Human genes 0.000 description 1
• 108010090319 Semaphorin-3A Proteins 0.000 description 1
• 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
• 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
• 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 1
• 108010011732 Steroid 21-Hydroxylase Proteins 0.000 description 1
• 102000014169 Steroid 21-Hydroxylase Human genes 0.000 description 1
• 102100027545 Steroid 21-hydroxylase Human genes 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 206010061372 Streptococcal infection Diseases 0.000 description 1
• 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
• 206010043515 Throat cancer Diseases 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 102100026160 Tomoregulin-2 Human genes 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 102000006986 U2 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
• 108010072724 U2 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
• 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 206010052568 Urticaria chronic Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 229950005186 abagovomab Drugs 0.000 description 1
• 229960003697 abatacept Drugs 0.000 description 1
• 229960000446 abciximab Drugs 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000009858 acid secretion Effects 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 229960003227 afelimomab Drugs 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• 229950009106 altumomab Drugs 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 229950005794 anrukinzumab Drugs 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003208 anti-thyroid effect Effects 0.000 description 1
• 239000002518 antifoaming agent Substances 0.000 description 1
• 229940043671 antithyroid preparations Drugs 0.000 description 1
• 229950003145 apolizumab Drugs 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 229940092117 atgam Drugs 0.000 description 1
• 229950005122 atinumab Drugs 0.000 description 1
• 208000026764 autoimmune bullous skin disease Diseases 0.000 description 1
• 229950001863 bapineuzumab Drugs 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 238000002869 basic local alignment search tool Methods 0.000 description 1
• 229950000321 benralizumab Drugs 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 229950010015 bertilimumab Drugs 0.000 description 1
• 108010023562 beta 2-Glycoprotein I Proteins 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 229950006326 bimagrumab Drugs 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 229950002903 bivatuzumab Drugs 0.000 description 1
• 229960003008 blinatumomab Drugs 0.000 description 1
• 239000003114 blood coagulation factor Substances 0.000 description 1
• 229940019700 blood coagulation factors Drugs 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 229950005042 blosozumab Drugs 0.000 description 1
• 201000006491 bone marrow cancer Diseases 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 229960000455 brentuximab vedotin Drugs 0.000 description 1
• 229960003735 brodalumab Drugs 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000002230 centromere Anatomy 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 238000011097 chromatography purification Methods 0.000 description 1
• 239000003593 chromogenic compound Substances 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 208000024376 chronic urticaria Diseases 0.000 description 1
• 235000013477 citrulline Nutrition 0.000 description 1
• 229960002173 citrulline Drugs 0.000 description 1
• 108010044493 collagen type XVII Proteins 0.000 description 1
• 230000005757 colony formation Effects 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 229960002482 dalotuzumab Drugs 0.000 description 1
• 229960002204 daratumumab Drugs 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 210000005045 desmin Anatomy 0.000 description 1
• 229950008962 detumomab Drugs 0.000 description 1
• 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
• 208000024637 distal renal tubular acidosis Diseases 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 229950003468 dupilumab Drugs 0.000 description 1
• 229950011453 dusigitumab Drugs 0.000 description 1
• 229960000284 efalizumab Drugs 0.000 description 1
• 229950002209 efungumab Drugs 0.000 description 1
• 229960004137 elotuzumab Drugs 0.000 description 1
• 229950002507 elsilimomab Drugs 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 229950003048 enavatuzumab Drugs 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229950000565 enlimomab pegol Drugs 0.000 description 1
• 229950007313 enokizumab Drugs 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
• 229950001757 epitumomab Drugs 0.000 description 1
• 229950004292 erlizumab Drugs 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• 229960004756 ethanol Drugs 0.000 description 1
• 229950004912 etrolizumab Drugs 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 208000001936 exophthalmos Diseases 0.000 description 1
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 229940093443 fanolesomab Drugs 0.000 description 1
• 229950001488 faralimomab Drugs 0.000 description 1
• 229950009929 farletuzumab Drugs 0.000 description 1
• 229950001563 felvizumab Drugs 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 229950008085 figitumumab Drugs 0.000 description 1
• 229950010320 flanvotumab Drugs 0.000 description 1
• 229950004923 fontolizumab Drugs 0.000 description 1
• 229950004356 foralumab Drugs 0.000 description 1
• 229950011078 foravirumab Drugs 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 229950009370 fulranumab Drugs 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• 229950004896 ganitumab Drugs 0.000 description 1
• 229950002508 gantenerumab Drugs 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 229950004792 gavilimomab Drugs 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 229960000578 gemtuzumab Drugs 0.000 description 1
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
• 229950003717 gevokizumab Drugs 0.000 description 1
• 229950009672 glembatumumab vedotin Drugs 0.000 description 1
• 210000000585 glomerular basement membrane Anatomy 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• 150000002339 glycosphingolipids Chemical class 0.000 description 1
• 201000003872 goiter Diseases 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 201000010235 heart cancer Diseases 0.000 description 1
• 208000024348 heart neoplasm Diseases 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 201000000284 histiocytoma Diseases 0.000 description 1
• 235000012907 honey Nutrition 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 229950010245 ibalizumab Drugs 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 229950002200 igovomab Drugs 0.000 description 1
• 229950005646 imgatuzumab Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229950007937 inolimomab Drugs 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 229950001014 intetumumab Drugs 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 229950010939 iratumumab Drugs 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 229950003818 itolizumab Drugs 0.000 description 1
• 108010028309 kalinin Proteins 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 229950000518 labetuzumab Drugs 0.000 description 1
• 229950000482 lampalizumab Drugs 0.000 description 1
• 108010032674 lampalizumab Proteins 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 229950002183 lebrikizumab Drugs 0.000 description 1
• 229950001275 lemalesomab Drugs 0.000 description 1
• 229950010470 lerdelimumab Drugs 0.000 description 1
• 229940121292 leronlimab Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229950005173 libivirumab Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 229950009923 ligelizumab Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229950002950 lintuzumab Drugs 0.000 description 1
• 201000006721 lip cancer Diseases 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229950011263 lirilumab Drugs 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 229950008083 maslimomab Drugs 0.000 description 1
• 229950008001 matuzumab Drugs 0.000 description 1
• 229950007254 mavrilimumab Drugs 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• 229950005555 metelimumab Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• 230000003228 microsomal effect Effects 0.000 description 1
• 210000001589 microsome Anatomy 0.000 description 1
• 229950003734 milatuzumab Drugs 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 229950002142 minretumomab Drugs 0.000 description 1
• 229950003063 mitumomab Drugs 0.000 description 1
• 229950005674 modotuximab Drugs 0.000 description 1
• 229950007699 mogamulizumab Drugs 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 229950008897 morolimumab Drugs 0.000 description 1
• 229960001521 motavizumab Drugs 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• 229960003816 muromonab-cd3 Drugs 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 230000001538 myasthenic effect Effects 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 229950007708 namilumab Drugs 0.000 description 1
• 229950008353 narnatumab Drugs 0.000 description 1
• 208000037830 nasal cancer Diseases 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 229950009675 nerelimomab Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 208000008795 neuromyelitis optica Diseases 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229950010203 nimotuzumab Drugs 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
• 229960003301 nivolumab Drugs 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 210000001623 nucleosome Anatomy 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 229950010465 odulimomab Drugs 0.000 description 1
• 229950008516 olaratumab Drugs 0.000 description 1
• 229950010006 olokizumab Drugs 0.000 description 1
• 229950000846 onartuzumab Drugs 0.000 description 1
• 210000005112 optic tract Anatomy 0.000 description 1
• 230000004421 optic tracts Effects 0.000 description 1
• 229950007283 oregovomab Drugs 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229950009723 ozanezumab Drugs 0.000 description 1
• 229950007318 ozogamicin Drugs 0.000 description 1
• 229950004327 ozoralizumab Drugs 0.000 description 1
• 108010051876 p80-coilin Proteins 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 229960000402 palivizumab Drugs 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 201000007052 paranasal sinus cancer Diseases 0.000 description 1
• 229950004260 parsatuzumab Drugs 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229950010966 patritumab Drugs 0.000 description 1
• 229960005570 pemtumomab Drugs 0.000 description 1
• 229940067082 pentetate Drugs 0.000 description 1
• 229950005079 perakizumab Drugs 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 229960002087 pertuzumab Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 229950010074 pinatuzumab vedotin Drugs 0.000 description 1
• 201000007315 pineal gland astrocytoma Diseases 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 229940126620 pintumomab Drugs 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229950009416 polatuzumab vedotin Drugs 0.000 description 1
• 229920000314 poly p-methyl styrene Polymers 0.000 description 1
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229950003486 ponezumab Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 229950009904 pritumumab Drugs 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 229950011639 radretumab Drugs 0.000 description 1
• 229950002786 rafivirumab Drugs 0.000 description 1
• 229960002633 ramucirumab Drugs 0.000 description 1
• 229960003876 ranibizumab Drugs 0.000 description 1
• 239000012429 reaction media Substances 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 229950005854 regavirumab Drugs 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
• 201000008946 renal pelvis neoplasm Diseases 0.000 description 1
• 201000010384 renal tubular acidosis Diseases 0.000 description 1
• 229960003254 reslizumab Drugs 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 229950003238 rilotumumab Drugs 0.000 description 1
• 229950001808 robatumumab Drugs 0.000 description 1
• 229950010699 roledumab Drugs 0.000 description 1
• 229950010968 romosozumab Drugs 0.000 description 1
• 229950010316 rontalizumab Drugs 0.000 description 1
• 229950009092 rovelizumab Drugs 0.000 description 1
• 229950005374 ruplizumab Drugs 0.000 description 1
• HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
• 229950000106 samalizumab Drugs 0.000 description 1
• 239000012898 sample dilution Substances 0.000 description 1
• 229950006348 sarilumab Drugs 0.000 description 1
• 229950007308 satumomab Drugs 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 229950008834 seribantumab Drugs 0.000 description 1
• 229950004951 sevirumab Drugs 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 229950008684 sibrotuzumab Drugs 0.000 description 1
• 229950010077 sifalimumab Drugs 0.000 description 1
• 229950009513 simtuzumab Drugs 0.000 description 1
• 229950003804 siplizumab Drugs 0.000 description 1
• 229950006094 sirukumab Drugs 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 229950007874 solanezumab Drugs 0.000 description 1
• 229950011267 solitomab Drugs 0.000 description 1
• 229950006551 sontuzumab Drugs 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 208000016765 streptococcal sore throat Diseases 0.000 description 1
• 229950010708 sulesomab Drugs 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 229950001915 suvizumab Drugs 0.000 description 1
• 229950010265 tabalumab Drugs 0.000 description 1
• 229950001072 tadocizumab Drugs 0.000 description 1
• 229950004218 talizumab Drugs 0.000 description 1
• 229950000864 technetium (99mtc) nofetumomab merpentan Drugs 0.000 description 1
• 229950001788 tefibazumab Drugs 0.000 description 1
• 229950008300 telimomab aritox Drugs 0.000 description 1
• CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
• 229950001289 tenatumomab Drugs 0.000 description 1
• 229950000301 teneliximab Drugs 0.000 description 1
• 229950010127 teplizumab Drugs 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 206010044008 tonsillitis Diseases 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229950001802 toralizumab Drugs 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 229950000835 tralokinumab Drugs 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 229950010086 tregalizumab Drugs 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 229950005082 tuvirumab Drugs 0.000 description 1
• 108010012374 type IV collagen alpha3 chain Proteins 0.000 description 1
• 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
• 229950005972 urelumab Drugs 0.000 description 1
• 201000000360 urethra cancer Diseases 0.000 description 1
• 201000001496 urethra transitional cell carcinoma Diseases 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 229950002148 vatelizumab Drugs 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229950000815 veltuzumab Drugs 0.000 description 1
• 229950005208 vepalimomab Drugs 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 230000007923 virulence factor Effects 0.000 description 1
• 239000000304 virulence factor Substances 0.000 description 1
• 229950003511 votumumab Drugs 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 229950008250 zalutumumab Drugs 0.000 description 1
• 229950009002 zanolimumab Drugs 0.000 description 1
• 229950001346 zolimomab aritox Drugs 0.000 description 1
• 108010027843 zonulin Proteins 0.000 description 1